EI
BMRN icon

EFG International’s BioMarin Pharmaceuticals BMRN Stock Holding History

EFG International’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Sell
18,400
-1,500
-8% -$82.2K 0.02% 415
2026
Q1 		$1.12M Hold
19,900
– – 0.02% 393
2025
Q4 		$1.18M Buy
+19,900
New +$1.08M 0.02% 362

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

EFG International's BMRN Position: Q2 2026 in Review

EFG International reduced its BioMarin Pharmaceuticals (BMRN) stake by 7.5% in Q2 2026, selling an estimated $82.2K and leaving 18,400 shares worth $1.05M. The position accounts for 0.02% of the portfolio, ranked #415.

EFG International first reported a position in BMRN in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.18M in Q4 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • EFG International held 18,400 shares of BioMarin Pharmaceuticals worth $1.05M as of Q2 2026.
  • EFG International sold 1,500 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $82.2K.
  • BioMarin Pharmaceuticals made up 0.02% of EFG International's portfolio in Q2 2026, its #415 holding.
  • EFG International first reported a position in BioMarin Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • EFG International's BioMarin Pharmaceuticals position peaked at $1.18M in Q4 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on EFG International's 13F filing for Q2 2026, filed 14 Aug 2026.